{
    "nctId": "NCT05475678",
    "briefTitle": "Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer",
    "officialTitle": "A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Triple Negative Breast Cancer, Camrelizumab",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 369,
    "primaryOutcomeMeasure": "Pathological complete response rate (pCR rate)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: 18-70 years old\n2. cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically\uff1b\n3. Pathologically proven triple negative breast cancer:\n\n   Triple-negative breast cancer is defined as:\n   * Negative for ER and PR (IHC nuclear staining \\<10%)\n   * Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH)\uff1b\n4. Has clinically measurable lesions:Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization\uff1b\n5. Organ and bone marrow function tests within 1 month before chemotherapy suggest no contraindications to chemotherapy\uff1b\n6. Cardiac ultrasound EF value \u226755%\uff1b\n7. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization;\n8. ECOG score\u22641 point;\n9. Sign informed consent\uff1b\n\nExclusion Criteria:\n\n1. The patient has evidence of metastatic breast cancer\uff1b\n2. For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received;\n3. The patient has a second primary malignancy other than adequately treated skin cancer;\n4. The patient has been treated with anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy\uff1b\n5. The patient has been diagnosed with immunodeficiency disease or autoimmune disease;\n6. The patient has severe lung or heart disease;\n7. The patient has active hepatitis B and C;\n8. The patient has a history of organ transplantation or bone marrow transplantation;\n9. pregnant or breastfeeding women;\n10. The investigators considered chemotherapy contraindicated due to serious, uncontrolled other medical conditions.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}